Regeneron Pharmaceuticals Inc. (REGN) News
Filter REGN News Items
REGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
REGN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest REGN News From Around the Web
Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.
Why Regeneron (REGN) is Poised to Beat Earnings Estimates AgainRegeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
How to Boost Your Portfolio with Top Medical Stocks Set to Beat EarningsWhy investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of R |
Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorderThe decision follows a positive recommendation received from the Committee for Medicinal Products for Human Use (CHMP) in November 2024. |
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall StreetBiotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) started 2024 on a strong note and performed well through the first half of the year. Regeneron's stock could soar by 50% in the next year from its current levels if we go by its average price target of $1,053 (according to Yahoo! Should investors rush to buy Regeneron's shares? |
Jim Cramer’s Take on Regeneron Pharmaceuticals (REGN): Bold Predictions for the FutureWe recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been one of Jim Cramer’s favorite topics lately. […] |
Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five yearsThe last three months have been tough on Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders, who have seen... |
Are You a Value Investor? This 1 Stock Could Be the Perfect PickThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Regeneron says study data support big bet on new blood thinnersThe company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials. |
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept ResultsInvestigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and REGN9933 administered 12 to 24 hours after total knee replacement demonstrated robust antithrombotic effects Phase 3 program to be initiated in 2025 TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regene |